• Link to Facebook
  • Link to LinkedIn
  • Link to X
  • Link to Instagram
  • Link to Youtube
  • Link to Mail
  • Link to Rss this site
  • Log In
    • Register
Contacts us @ MediPr.org
Medical News Asia | Powered by ['mediPr]
  • MDnews
  • About [‘mediPr]
  • HER2 Explorer
  • TROP Tool
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Scroll to next section Scroll to next section

Non-Sponsored Content

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail


MEDICAL NEWS ASIA

Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

By: Stijn van den Borne, MSc | Last updated: 16 January 2019 | In: Medical News Asia, Oncology, Surgery

Article Keywords

NovusScientific, resorbable mesh, surgical matrix, surgical mesh, synthetic mesh, TIGR, hernia

UPPSALA, Sweden, Jan. 16, 2019 /PRNewswire/ — The synthetic and fully resorbable TIGR®Matrix surgical mesh (Novus Scientific AB, Uppsala − Sweden) might be an interesting candidate for the prevention of complications frequently observed with permanent mesh placement, according to Professor Johan Lange of the Erasmus University in Rotterdam − the Netherlands.

A common complication occurring in about 20% of patients undergoing laparotomy is incisional hernia – the protruding of abdominal organs due to surgery-related tissue weakness.

“Recent research by the R.E.P.A.I.R. study group of the Erasmus University Medical Center has shown that surgical matrices can prevent incisional hernia after laparotomy, but it is well known that permanent meshes can cause severe complications, including seromas, infections, and persistent pain.1Jairam AP, et al. Lancet. 2017 Aug 5;390(10094): DOI:10.1016/S0140-6736(17)31332-6. There is an unmet need for an effective and safer alternative to permanent meshes for several indications in abdominal wall hernia surgery,” explained Professor Lange.

A smaller trial in sixteen patients undergoing laparotomy and at risk of incisional hernia reported promising results using onlay TIGR®Matrix placement.2Söderbäck H, et al. Front Surg. 2016;3(28): DOI:10.3389/fsurg.2016.00028.The study had a low complication-rate of 12.5% with an exciting efficacy: no cases of incisional hernia occurred.

“Researchers of the R.E.P.A.I.R.-group at the Erasmus University Medical Center are now initiating a large, multicentre, clinical study in 70 patients undergoing midline surgery to investigate the short- and long-term safety and efficacy of onlay TIGR®Matrix surgical mesh,” said lead-investigator of the study Professor Lange. “This study will show if the earlier, positive results with the fully resorbable synthetic mesh can be confirmed.”

Professor Johan Lange has published over 300 articles in peer-reviewed journals, including a recent study comparing sublay and onlay surgical mesh for the prevention of incisional hernia.1Jairam AP, et al. Lancet. 2017 Aug 5;390(10094): DOI:10.1016/S0140-6736(17)31332-6.

About the TIGR®Matrix

TIGR®Matrix is the first long-term resorbable, 100% synthetic, surgical mesh. Its unique technology consisting of dual-stage degradation and full resorption, paired with ease of use, is a significant step forward in surgical mesh technology.

The fast-degrading part improves the mesh’s flexibility and stretchability, provides extra strength during the immediate healing phase, and gradually absorbs during the first four months. The slow-degrading part of the mesh provides optimal strength for up to nine months with complete resorption in approximately three years. TIGR®Matrix uses 100% synthetic polymers that are well documented, clinically proven, and commonly used in medical devices since the 1970s.

About the Novus Scientific

Novus Scientific AB (www.novusscientific.com) develops, manufactures and markets resorbable implants that help the body’s own healing. The headquarter, research and production facilities are located in Uppsala, Sweden.

Source

  1. Jairam AP, et al. Lancet. 2017 Aug 5;390(10094): DOI:10.1016/S0140-6736(17)31332-6.
  2. Söderbäck H, et al. Front Surg. 2016;3(28): DOI:10.3389/fsurg.2016.00028.


Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

YOU MAY ALSO LIKE

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

© Copyright 2018 MediPaper Medical Communications Ltd. – Erasmus University MC investigating a new surgical matrix to reduce post-operative complications

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail

YOU MAY ALSO LIKE

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

© Copyright 2018 MediPaper Medical Communications Ltd. – PolyU Researcher Develop Novel Self-fitting Scaffold for Bone-Regeneration

Categories

Categories

Newsletter


 [‘mediPr] | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | CORTiX AI for Medical Science | Dub-Dub Subtitle Generation
© 2016-2026 MediPaper Medical Communications Ltd. | Website by [’mediPr] Sydney | Singapore | Hong Kong | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Link to Facebook
  • Link to LinkedIn
  • Link to X
  • Link to Instagram
  • Link to Youtube
  • Link to Mail
  • Link to Rss this site
Link to: Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma Link to: Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma Link to: Cabozantinib FDA approved in HCC patients failing sorafenib Link to: Cabozantinib FDA approved in HCC patients failing sorafenib Cabozantinib FDA approved in HCC patients failing sorafenib
Scroll to top Scroll to top Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings×

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

5
Accept settingsHide notification only